FDA grants fast track to alpha-1 antitrypsin deficiency-related liver disease drug

The FDA granted fast track designation to ARO-AAT, Arrowhead Pharmaceuticals’ second generation subcutaneously administered RNA interference therapeutic, for the treatment of alpha-1 antitrypsin deficiency-related liver disease, according to a press release.
Arrowhead also announced that the company is in final preparations to initiate SEQUOIA (AROAAT2001), a phase 2/3 clinical study in the U.S. and Europe, and AROAAT2002, a phase 2 open-label clinical study in Europe.
“With no currently approved agents to treat AATD-associated liver disease, alpha-1 patients and their physicians

Source link

Related posts

Digesting the Role of Diet in Patients With IBD


Diet changes in young adults may quickly reduce depression symptoms


Get Your Colon Screen in ’19: Download CRC Awareness Graphics


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World